

# Diagnostic and prognostic value of Sepsis-Induced coagulopathy and International Society on Thrombosis and Hemostasis scoring systems in COVID-19-associated disseminated intravascular coagulopathy

Sayyideh Forough Hosseini<sup>1</sup>, Sahar Behnam- Roudsari<sup>1</sup>, Ghazal Alavinia<sup>1</sup>, Anahita Emami<sup>1</sup>, Arash Toghyani<sup>2</sup>, Sanaz Moradi<sup>1</sup>, Mahtab Mojtahed Zadeh<sup>1</sup>, Sana Mohseni<sup>1</sup>, Mohammad Ali Shafiee<sup>1</sup>

<sup>1</sup>Department of Medicine, Division of General Internal Medicine, Toronto General Hospital, Toronto, Canada, <sup>2</sup>Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

**Background:** The coronavirus disease 2019 (COVID-19) presents various phenotypes from asymptomatic involvement to death. Disseminated intravascular coagulopathy (DIC) is among the poor prognostic complications frequently observed in critical illness. To improve mortality, a timely diagnosis of DIC is essential. The International Society on Thrombosis and Hemostasis (ISTH) introduced a scoring system to detect overt DIC (score  $\geq 5$ ) and another category called sepsis-induced coagulopathy (SIC) to identify the initial stages of DIC (score  $\geq 4$ ). This study aimed to determine whether clinicians used these scoring systems while assessing COVID-19 patients and the role of relevant biomarkers in disease severity and outcome. **Materials and Methods:** An exhaustive search was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses, using Medline, Embase, Cochrane, CINAHL, and PubMed until August 2020. Studies considering disease severity or outcome with at least two relevant biomarkers were included. For all studies, the definite, maximum, and minimum ISTH/SIC scores were calculated. **Results:** A total of 37 papers and 12,463 cases were reviewed. Studies considering ISTH/SIC criteria to detect DIC suggested a higher rate of ISTH  $\geq 5$  and SIC  $\geq 4$  in severe cases and nonsurvivors compared with nonsevere cases and survivors. The calculated ISTH scores were dominantly higher in severe infections and nonsurvivors. Elevated D-dimer was the most consistent abnormality on admission. **Conclusion:** Higher ISTH and SIC scores positively correlate with disease severity and death. In addition, more patients with severe disease and nonsurvivors met the ISTH and SIC scores for DIC. Given the high prevalence of coagulopathy in COVID-19 infection, dynamic monitoring of relevant biomarkers in the form of ISTH and SIC scoring systems is of great importance to timely detect DIC in suspicious patients.

**Key words:** Coagulopathy, coronavirus disease 2019, disseminated intravascular coagulation, International Society on Thrombosis and Hemostasis, sepsis-induced coagulopathy score

**How to cite this article:** Hosseini SF, Behnam-Roudsari S, Alavinia G, Emami A, Toghyani A, Moradi S, *et al.* Diagnostic and prognostic value of sepsis-induced coagulopathy and International Society on Thrombosis and Hemostasis scoring systems in COVID-19-associated disseminated intravascular coagulopathy. *J Res Med Sci* 2021;26:102.

## INTRODUCTION

The novel coronavirus disease 2019 (COVID-19) presents with various features ranging from

asymptomatic and mild disease to life-threatening conditions and death.<sup>[1,2]</sup> Since the disease outbreak, many studies have focused on COVID-associated coagulopathy and its prognostic significance in disease

### Access this article online

Quick Response Code:



Website:

[www.jmsjournal.net](http://www.jmsjournal.net)

DOI:

10.4103/jrms.JRMS\_1295\_20

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

**For reprints contact:** WKHLRPMedknow\_reprints@wolterskluwer.com

**Address for correspondence:** Dr. Mohammad Ali Shafiee, Department of Medicine, Division of General Internal Medicine, Royal College Mentor, University of Toronto, Toronto General Hospital, 200 Elizabeth Street, 14 EN-208 Toronto, Canada.

E-mail: [mohammad.shafiee@uhn.ca](mailto:mohammad.shafiee@uhn.ca)

**Submitted:** 07-Dec-2020 **Revised:** 30-Dec-2020 **Accepted:** 25-Mar-2021 **Published:** 18-Oct-2021

severity and mortality rate.<sup>[3,4]</sup> Accumulated data revealed that in COVID-19 infection, the excessive inflammatory response, platelet aggregation, endothelial injury, and stasis cause systemic arterial, venous and capillary thrombosis. This results in laboratory changes such as lymphopenia, elevated lactate dehydrogenase, marked D-dimer, increased C-reactive protein, mild prothrombin time (PT) prolongation, and mild thrombocytopenia. Clinical manifestations include deep vein thrombosis, pulmonary embolism, disseminated intravascular coagulopathy (DIC), myocardial ischemia, acute kidney injury, acute mesenteric ischemia, and brain stroke.<sup>[5,6]</sup> DIC is one of the most poor-prognostic complications identified in COVID-19 patients. In a retrospective review of 183 COVID-19 cases, DIC appeared in over two-third of nonsurvivors and <1% of survivors, indicating a prognostic value of DIC in disease severity and outcome.<sup>[4]</sup>

Like other underlying etiologies, COVID-associated DIC is caused by dysregulation of the delicately balanced coagulation and fibrinolysis system, which leads to consumptive coagulopathy and presents with widespread clotting and concomitant bleeding.<sup>[7-10]</sup> However, unlike the classic pattern, COVID-associated DIC predominantly features thromboembolism rather than hyperfibrinolysis, resulting in adverse thromboembolic outcomes such as hypoperfusion and multi-organ damage.<sup>[10-12]</sup> It has been proposed that the early recognition and management of DIC in COVID-19 patients plays a fundamental role in reducing the death toll.<sup>[10]</sup>

There is no single biomarker of high certainty for the diagnosis of DIC. However, a combination of biomarkers changes, especially when repeated in a patient with clinical suspicion of DIC, can be used as a diagnostic tool with acceptable certainty. In 2001, the International Society on Thrombosis and Hemostasis (ISTH) launched a laboratory-based scoring system using platelet count, D-Dimer or fibrin degradation products (FDP), PT, and fibrinogen for diagnosis of DIC, with a score  $\geq 5$  being indicative of overt DIC.<sup>[11]</sup> To more accurately identify septic patients who were inclined to DIC, sepsis-induced coagulopathy (SIC) scoring system was introduced in 2017. It evaluates patients based on Sequential Organ Failure Assessment (SOFA) score; an indicator of four organs' function (respiratory, cardiovascular, hepatic, and renal); together with platelet count and international normalized ratio (INR) and suggests that patients with SIC score  $\geq 4$  are at an increased chance of developing overt DIC.<sup>[13]</sup>

Regarding the fact that DIC is a dynamic process,<sup>[14]</sup> regular monitoring of pertinent biomarkers in the disease course is pivotal to detect DIC in optimum time for planning treatments.<sup>[15]</sup> Previous reports of patients who died of an

aggravated COVID-19 infection highlighted a noticeable rise in PT and D-dimer levels and a decrease in fibrinogen level in days 10–14 of disease onset.<sup>[4]</sup> Besides, the administration of anticoagulants in the initial stages of DIC (SIC  $\geq 4$ ) has offered significantly improved outcomes and mortality in COVID-19 patients, according to prior studies.<sup>[10]</sup>

Given the crucial role of diagnosis and treatment of DIC in preventing drastic complications and declining mortality,<sup>[10,16,17]</sup> the present systematic review aimed to explore whether clinicians considered ISTH/SIC criteria a valid scoring system for DIC detection and the value of these scores in predicting disease severity and mortality.

## MATERIALS AND METHODS

### Search strateg

A systematic literature search was conducted to assess the diagnostic value of ISTH criteria in patients with COVID-19, using Medline, Embase, Cochrane, and Cochrane Database of Systematic Reviews via Ovid, CINAHL through Ebsco, and PubMed until August 2020. Relevant articles were captured applying MeSH terms “ISTH,” “coagulopathy,” “DIC,” and “D-dimer” and “prothrombin time” and then added to the terms “COVID” OR “coronavirus” OR “SARS-Cov-2,” including possible adjacencies adjusted consistently for various databases. All studies were having the reports of relevant coagulation biomarkers (platelet count, D-dimer/FDP, PT/INR, Fibrinogen, and SOFA score) with regard to survival outcomes (survivors/nonsurvivors) and disease severity (severe/nonsevere disease) were included. The exclusion criteria were as follows: 1 - studies reporting <2 relevant coagulation biomarkers, 2 - case reports, reviews, conference abstracts, and studies published in a language other than English, 3 - studies conducted on children, pregnant population or patients with certain underlying conditions (chronic kidney disease, cardiovascular disease, respiratory disorders, etc.). Relevant abstracts and those needing further investigation were considered for full-text review, and eligible studies were included for data extraction. We also screened reference lists from included full-text articles. Publication review, screening, and data extraction were done by two investigators (HF and BRS) independently, and disagreements were discussed with the third author (MS).

To address the research question data regarding authors, year, study design, sample size, platelet count, D-dimer, FDP, PT, INR, fibrinogen, SOFA score, and the reports on ISTH/SIC, scores were extracted and arranged into a Microsoft Excel spreadsheet. Enrolled papers were categorized into two main groups based on disease severity (severe vs. nonsevere) and survival outcome (survivors vs. nonsurvivors). In terms of disease

severity, in studies classifying patients into three or four groups (mild/moderate/severe/critical), data were manually integrated, considering mild to moderate involvement as nonsevere and severe to critical involvement as severe. Intensive care unit (ICU) admission was also accounted for a severe illness in contrast to non-ICU admission. Then, to further evaluate the role of ISTH and SIC in COVID-19 in studies not reporting these scores, the definite, maximum, and minimum ISTH and SIC scores were calculated. In studies having all relevant lab data, the definite ISTH and SIC scores were measured and reported. In studies with missing data, the minimum and maximum scores of ISTH (Min-ISTH and Max-ISTH) and SIC (Min-SIC and Max-SIC) were calculated considering the highest and the lowest possible points for the undocumented markers. The quality of the studies was evaluated using the Newcastle Ottawa Scale assessment form.<sup>[18]</sup>

### Description of the method used for calculating the definite, minimum, and maximum scores of International Society on Thrombosis and Hemostasis and sepsis-induced coagulopathy

The distribution of points in the ISTH and SIC scoring systems is shown in Table 1. In studies with complete data for calculating ISTH and SIC, we reported the definite score by adding available points. We calculated the minimum and maximum scores by considering the lowest (0) and the highest possible points for the absent data in studies with missing data. For instance, in a study by He *et al.*,<sup>[19]</sup> the reported markers in severely ill patients were D-dimer = 9.89 µg/mL (reference range = 0–0.55), PT = 13 sec (reference range = 9–13 s), and fibrinogen = 3.3 g/L (reference range = 2–4) and the absent marker was platelet count. We summed the available points to calculate the min-ISTH: D-dimer >4 times ULN = 3 points, PT <3 s prolongation = 0 point, fibrinogen >1 = 0 point, and the Min-ISTH of 3 was obtained. To calculate the Max-ISTH, we considered the highest possible point for the absent marker (platelet <100,000 = 2 points) and added it to the minimum score (3); thus, the max-ISTH of 5 was achieved. We followed the same instruction for measuring the minimum and maximum SIC scores.

## RESULTS

A comprehensive search yielded 842 studies. After title and abstract screening and excluding duplicates ( $n = 739$ ), 103 articles were selected for full-text screening. Of these, 37 were included in the review, following the exclusion of irrelevant articles. We also found 14 studies using backward citation searching (checking reference lists). Figure 1 shows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses flowchart for the article selection process.<sup>[20]</sup>

**Table 1: International Society on Thrombosis and hemostasis and sepsis-induced coagulopathy scoring systems for disseminated intravascular coagulopathy diagnosis**

Items	ISTH	SIC	Points
Platelet count ( $\times 10^9/L$ )	$\geq 100$	$\geq 150$	0
	50-100	100-150	1
	<50	<100	2
D-Dimer elevation or FDP elevation (mg/L)	<2 times ULN	-	0
	2-4 times ULN	-	2
	>4 times ULN	-	3
	<10	-	0
	10-25	-	2
PT prolongation (s)/ INR increase	>25	-	3
	<3	<1.2	0
	3-6	1.2-1.4	1
Fibrinogen (g/L)	$\geq 3$	$\geq 1.4$	2
	>1	-	0
SOFA score	<1	-	1
	-	0	0
	-	1	1
	-	$\geq 2$	2

Overt DIC: ISTH score  $\geq 5$ , early stages of DIC: SIC score  $\geq 4$ . DIC=Disseminated intravascular coagulopathy; ISTH=International Society on Thrombosis and hemostasis; SIC=Sepsis-induced coagulopathy; FDP=Fibrin degradation products; PT=Prothrombin time; INR=International normalized ratio; SOFA=Sequential organ failure assessment

A total number of 37 papers, including 12,463 cases of COVID-19, were systematically reviewed. All articles were published in 2020, among which 20 reported data about disease severity and 17 about disease outcome. Nearly all of the selected papers had a retrospective design, and most of them were assessed as high quality.

Out of 37 selected studies, only six used the ISTH/SIC scoring systems to detect DIC in COVID-19 infection [Table 2].<sup>[4,10,21-24]</sup> The findings confirmed that the incidence of overt DIC was notably higher in critically ill patients and those who died. Data for calculating the definite score were complete only in five studies for ISTH,<sup>[21-25]</sup> which showed no difference between groups in three studies (the score of 0 for severe and nonsevere/survivors and nonsurvivors) [Table 3].

Table 4 describes the data related to the first group of studies that compares severe and nonsevere COVID-19 cases ( $n = 20$ ). The total number of severe cases was 3,359, and nonsevere cases were 4469 patients. Regarding the components of the ISTH scoring system, the platelet count was reported in 12 out of 20 studies,<sup>[1,21,22,25-33]</sup> all of which were within the normal range but with lower values in the severe compared to the nonsevere group in nine studies. Only five studies noted FDP levels, with marked elevation in severe versus nonsevere illness.<sup>[19,22,34-36]</sup> When looking at SIC scoring system components, five studies recorded INR,<sup>[21,34-37]</sup> and only two studies reported the SOFA score,<sup>[27,29]</sup> with remarkably higher scores in severe involvement. According




Figure 1: Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram

Table 2: The reported incidence of overt disseminated intravascular coagulopathy and early stages of disseminated intravascular coagulopathy

Author	ISTH score $\geq 5$ incidence	SIC score $\geq 4$ incidence
Bao <i>et al.</i> <sup>[21]</sup>	6.1% in severe cases versus 0% in nonsevere cases	-
Liao <i>et al.</i> <sup>[22]</sup>	15% in severe cases	-
Liu <i>et al.</i> <sup>[23]</sup>	57.1% in nonsurvivors versus 1.8% in survivors	-
Martin-Rojas <i>et al.</i> <sup>[24]</sup>	22.2% in nonsurvivors versus 3.7% in survivors	-
Tang <i>et al.</i> <sup>[4]</sup>	71.6% in nonsurvivors versus 0.6% in survivors	-
Tang <i>et al.</i> <sup>[10]</sup>	-	41% in nonsurvivors vs 13.3% in survivors

ISTH=International Society on Thrombosis and Hemostasis; SIC=Sepsis-induced coagulopathy

Table 3: The calculated definite scores of International Society on Thrombosis and hemostasis in coronavirus disease 2019 cases

Author	Nonsevere	Severe	Survivors	Nonsurvivors
Bao <i>et al.</i> <sup>[21]</sup>	0	0	-	-
Liao <i>et al.</i> <sup>[22]</sup>	0	3	-	-
Liu <i>et al.</i> <sup>[23]</sup>	-	-	2	3
Martin-Rojas <i>et al.</i> <sup>[24]</sup>	-	-	0	0
White <i>et al.</i> <sup>[25]</sup>	0	0	-	-

to Liu *et al.*, the SOFA score in moderate, severe, and critical COVID-19 infection was 0, 1, and 5, respectively.<sup>[29]</sup> In another study by Li *et al.*, the mean SOFA score was  $4.3 \pm 2.5$  in severe cases versus  $2.5 \pm 2.3$  in nonsevere.<sup>[27]</sup>

Table 5 displays the minimum and maximum ISTH and SIC scores calculated by the authors in severe and nonsevere

COVID-19 cases. In none of the included papers, Min-ISTH met the threshold either for overt DIC (ISTH  $\geq 5$ ) or early stages of DIC (SIC  $\geq 4$ ), while Max-ISTH reached the cutoff for overt DIC in five studies<sup>[19,34-36,38]</sup> in four of which only among the severe group and in one study in both groups. Except for six,<sup>[30-32,34,39,40]</sup> the rest 11 studies showed higher ISTH scores in severe than in nonsevere cases. SIC  $\geq 4$  was not met in any of the Min-ISTHs.

Table 6 demonstrates the comparison of the ISTH and SIC scoring systems components between COVID-19 survivors and nonsurvivors ( $n = 17$ ). The total number of patients who died due to COVID-19 and who recovered were 1280 and 3355, respectively. The lowest reported platelet count was 90,500 in nonsurvivors,<sup>[44]</sup> which reached the introduced platelet threshold for escalating the score in both ISTH and SIC (1 and 2 points, respectively). Fibrinogen level

**Table 4: The most reported international society on thrombosis and hemostasis and sepsis-induced coagulopathy parameters in nonsevere and severe cases of coronavirus disease 2019**

Author/study design	Sample size	PLT x 1000		D-dimer (µg/mL)/FDP (mg/L)		Fibrinogen (g/L)		PT (s)/INR	
		Nonsevere	Severe	Nonsevere	Severe	Nonsevere	Severe	Nonsevere	Severe
Bao et al. <sup>[121]</sup> /prospective cohort	178	251	186	0.42	1.05	3.23	3.62	12.7/1.06	14.5/1.21
Gao et al. <sup>[139]</sup> /retrospective cohort	43	NR	NR	0.21	0.49	3.11±0.83	3.84±1.00	11.26±1.42	12.03±1.21
Han et al. <sup>[134]</sup> /retrospective cohort	94	NR	NR	2.14/7.92	19.39/62.04	5.1	4.94	12.2/1.04	12.68/1.09
He et al. <sup>[109]</sup> /retrospective case series	53	NR	NR	0.38/0.9	9.89/32.7	3.6	3.3	12	13
Huang et al. <sup>[11]</sup> /prospective cohort	41	149	196	0.5	2.4	NR	NR	10.7	12.2
Huang et al. <sup>[126]</sup> /retrospective cohort	125	206.01±55.61	182.46±55.47	0.780	1.760	NR	NR	13.66±0.89	13.80±1.70
Li et al. <sup>[127]</sup> /retrospective cohort	312	233.7±92.6	157.4±95.3	0.5±0.3	4.8±2.1	NR	NR	12.7±5.4	14.8±4.5
Li et al. <sup>[128]</sup> /retrospective cohort	193	196	165	0.57	1.18	NR	NR	13.6	13.5
Liao et al. <sup>[122]</sup> /retrospective cohort	380	198	181.5	0.42/1.9	3.54/13.1	4.29	4.48	13	14.7
Long et al. <sup>[138]</sup> /retrospective case series	115	NR	NR	0.85	2.54	4.38	4.73	12.34	12.71
Liu et al. <sup>[120]</sup> /retrospective cohort	2044	229	208	0.47	1.80	NR	NR	13.6	14.26
Liu et al. <sup>[137]</sup> /retrospective cohort	122	NR	NR	0.59	1.06	4.2	4.7	10.9/0.93	11.7/0.99
Qian et al. <sup>[130]</sup> /retrospective case series	91	198	152	0.3	0.45	3.36	3.8	NR	NR
Wang et al. <sup>[131]</sup> /retrospective case series	138	165	142	0.166	0.414	NR	NR	12.9	13.2
White et al. <sup>[125]</sup> /retrospective cross-sectional	109	221	288	0.323	0.555	4.33	6.42	13.3	13.6
Yu et al. <sup>[132]</sup> /retrospective case series	1663	213	237	0.6	0.9	NR	NR	13.7	13.9
Yu et al. <sup>[135]</sup> /retrospective cohort	1561	NR	NR	0.5/4	1.8/6.5	NR	NR	13.35/1	14.4/1.1
Zeng et al. <sup>[140]</sup> /retrospective cohort	274	NR	NR	0.28	1.6	NR	NR	13.35	13.7
Zhang et al. <sup>[133]</sup> /retrospective case series	221	175	169	0.184	0.443	NR	NR	12.7	13.4
Zhang et al. <sup>[136]</sup> /retrospective cohort	71	NR	NR	0.44/2.4	5.95/13	3.96	3.84	11.5/1.02	12/1.07

PLT=Platelet count; FDP=Fibrin degradation product; PT=Prothrombin time; INR=International normalized ratio

**Table 5: The calculated minimum and maximum scores of International Society on Thrombosis and Hemostasis and sepsis-induced coagulopathy in severe and nonsevere coronavirus disease 2019 cases**

Author/study design	Minimum-ISTH		Maximum-ISTH		Minimum-SIC		Maximum-SIC	
	Nonsevere	Severe	Nonsevere	Severe	Nonsevere	Severe	Nonsevere	Severe
Bao <i>et al.</i> <sup>[21]</sup> /prospective cohort	-	-	-	-	0	1	2	3
Gao <i>et al.</i> <sup>[39]</sup> /retrospective cohort	0	0	2	2	0	0	6	6
Han <i>et al.</i> <sup>[34]</sup> /retrospective cohort	3	3	5	5	0	0	4	4
He <i>et al.</i> <sup>[19]</sup> /retrospective case series	0	3	2	5	0	0	6	6
Huang <i>et al.</i> <sup>[11]</sup> /prospective cohort	0	2	1	3	1	0	5	4
Huang <i>et al.</i> <sup>[26]</sup> /retrospective cohort	0	2	1	3	0	0	4	4
Li. T <i>et al.</i> <sup>[27]</sup> /retrospective cohort	0	3	1	4	0	0	4	4
Li <i>et al.</i> <sup>[28]</sup> /retrospective cohort	0	2	1	3	0	0	4	4
Liao <i>et al.</i> <sup>[22]</sup> /retrospective cohort	-	-	-	-	0	0	4	4
Long <i>et al.</i> <sup>[38]</sup> /retrospective case series	0	3	2	5	0	0	6	6
Liu <i>et al.</i> <sup>[29]</sup> /retrospective cohort	0	2	1	3	0	2	2	4
Liu <i>et al.</i> <sup>[37]</sup> /retrospective cohort	0	2	2	4	0	0	4	4
Qian <i>et al.</i> <sup>[30]</sup> /retrospective case series	0	0	2	2	0	0	4	4
Wang <i>et al.</i> <sup>[31]</sup> /retrospective case series	0	0	1	1	0	3	4	5
White <i>et al.</i> <sup>[25]</sup> /retrospective cross-sectional	-	-	-	-	0	0	4	4
Yu <i>et al.</i> <sup>[32]</sup> /retrospective case series	0	0	1	1	0	0	4	4
Yu <i>et al.</i> <sup>[35]</sup> /retrospective cohort	0	2	3	5	0	0	4	4
Zeng <i>et al.</i> <sup>[40]</sup> /retrospective cohort	0	2	2	4	0	0	6	6
Zhang <i>et al.</i> <sup>[33]</sup> /retrospective case series	0	0	1	1	0	0	4	4
Zhang <i>et al.</i> <sup>[36]</sup> /retrospective cohort	0	3	2	5	0	0	4	4

ISTH=International Society on Thrombosis and Hemostasis; SIC=Sepsis-induced coagulopathy

was only reported in three studies, which was 5 vs. 4.9,<sup>[23]</sup> 5.75 ± 1.83 vs. 5.26 ± 2.26,<sup>[24]</sup> and 4.51 vs. 5.16<sup>[41]</sup> in survivors and nonsurvivors, respectively. As for the SIC parameters, data on SOFA scores were present in six studies, all of which highlighted higher scores in the deceased versus the recovered.<sup>[23,44,49,51,52,53]</sup> Only two studies provided data on INR, which were higher among COVID-19 patients who failed to survive.<sup>[24,43]</sup>

Table 7 reflects the calculated minimum and maximum ISTH and SIC scores in COVID-19 survivors and nonsurvivors. The highest Min-ISTH was 4, which was obtained among nonsurvivors in two studies.<sup>[10,44]</sup> ISTH ≥5 appeared in Max-ISTH for the nonsurvivors of four studies,<sup>[10,44,45,47]</sup> and SIC ≥4 was only fulfilled in Min-ISTH of one study for nonsurvivors.<sup>[44]</sup> In 80% of the calculated ISTH scores, the score was higher among the deceased, mainly as a result of a sharper rise in D-dimer level in this population.

## DISCUSSION

Considering the poor prognosis of DIC, there is little doubt that DIC's diagnosis and risk classification plays a pivotal role in the triage, prognosis, and management of COVID-19 patients, especially in critical cases. ISTH proposes applicable, highly valid, and laboratory-based scoring systems for identifying patients with overt DIC and septic patients inclined to DIC regardless of their clinical symptoms.<sup>[54,55]</sup> This systematic review revealed

that although many studies did not systematically evaluate ISTH parameters in COVID-19 patients, based on available data, patients with higher ISTH/SIC scores had a higher likelihood of disease severity, death, and the need for special treatment strategies such as ICU admission and mechanical ventilation. Additionally, it was shown that when calculating the maximum scores for missing ISTH parameters in COVID-19 patients enrolled in the reviewed studies, patients with more severe disease and nonsurvivors received higher scores compared to patients with the nonsevere disease and those who survived, which signified the importance of timely and precise DIC risk stratification to adjust treatment and achieve better outcomes.

Only a few studies among the reviewed articles have reported ISTH scores or systematically assessed all biomarkers required for calculating ISTH and SIC scores among patients with moderate, severe, and critical COVID-19. However, these few studies confirmed that the DIC scoring system is a strong independent predictor of a fatal outcome in COVID-19 patients. Tang *et al.* research has revealed that 71.4% of nonsurvivor COVID-19 patients fulfilled the ISTH criteria for overt DIC (≥5 points), compared with only 0.6% survivors.<sup>[4]</sup> Moreover, in another study by Tang *et al.*, in severely ill patients with SIC ≥ 4, those who received heparin had a significantly lower 28-day mortality rate compared with those who did not (40% vs. 64.2%,  $P = 0.029$ ). It appears that anticoagulant treatment in this population might postpone or even reverse the harmful

**Table 6: The most reported International Society on Thrombosis and Hemostasis and sepsis-induced coagulopathy parameters in coronavirus disease 2019 survivors and nonsurvivors**

Author/study design	Sample size	PLT x1000		D-dimer (µg/mL)/FDP (mg/L)		SOFA score		PT (sec)/INR	
		Survivors	Nonsurvivors	Survivors	Nonsurvivors	Survivors	Nonsurvivors	Survivors	Nonsurvivors
Ronderos Botero et al. <sup>[41]</sup> /retrospective cohort	157	218.4±96.2	219.3±111	1.682±4.759	8.705±17.608	NR	NR	13.3±1.8	14±1.9
Chen et al. <sup>[42]</sup> /retrospective case series	274	198	156	1.1	4.6	NR	NR	13.9	15.5
Giusti et al. <sup>[43]</sup> /prospective cohort	209	189	174	0.739	1.149	NR	NR	13.8±2.4/1.22±0.21	15.2±3.1/1.31±0.21
Liu et al. <sup>[44]</sup> /retrospective cohort	1190	201	90.5	0.8	17.8	2	10	11.4	14
Liu et al. <sup>[23]</sup> /retrospective cohort	147	221	155	1.3/4.8	7.8/70.8	1	5	14.3	15.9
Luo et al. <sup>[45]</sup> /retrospective cohort	403	205	169	0.5	5.38	NR	NR	NR	NR
Martin-Rojas et al. <sup>[24]</sup> /retrospective cohort	206	262	203	0.385	1.472	NR	NR	12.7/1.13	14/1.25
Shang et al. <sup>[46]</sup> /retrospective cohort	113	160	142	0.23	3.4	NR	NR	13.1	13.3
Tang et al. <sup>[41]</sup> /retrospective cohort	183	NR	NR	0.61/4	2.12/7.6	NR	NR	13.6	15.5
Tang et al. <sup>[40]</sup> /retrospective cohort	449	231±99	178±92	1.47	4.70	NR	NR	14.6±2.1	16.5±8.4
Wang et al. <sup>[47]</sup> /training cohort	296	NR	NR	0.2	0.5	NR	NR	13.3±1.9	13.7±1.9
Wang et al. <sup>[47]</sup> /validation cohort	44	NR	NR	0.6	1.1	NR	NR	13.2±0.8	14.1±1.2
Wang et al. <sup>[48]</sup> /retrospective cohort	339	211	172	1.08	4.38	NR	NR	12	12.9
Wang et al. <sup>[49]</sup> /retrospective case series	59	192.2±85.5	145.8±71.1	6.1±8.0/36.6±56	12.0±9.7/76.8±63.9	3.4±3.3	8.9±9.5	15.3±1.5	16.7±4.3
Wu et al. <sup>[50]</sup> /retrospective cohort	84	204	162	0.49	3.95	NR	NR	11.75	11.6
Xu et al. <sup>[51]</sup> /retrospective cohort	239	186	160	NR	NR	5	6	11.6±1.4	12.0±1.
Yang et al. <sup>[52]</sup> /retrospective cohort	52	164	191	NR	NR	4	6	10.9	12.9
Zhou et al. <sup>[53]</sup> /retrospective cohort <sup>[53]</sup>	191	220	165.5	0.6	5.2	1	4.5	11.4	12.1

PLT=Platelet count; FDP=Fibrin degradation product; SOFA=Sequential organ failure assessment; PT=Prothrombin time; INR=International normalized ratio

**Table 7: The calculated minimum and maximum scores of International Society on Thrombosis and Hemostasis and sepsis-induced coagulopathy in coronavirus disease 2019 survivors and nonsurvivors**

Author/study design	Minimum-ISTH		Maximum-ISTH		Minimum-SIC		Maximum-SIC	
	Survivors	Nonsurvivors	Survivors	Nonsurvivors	Survivors	Nonsurvivors	Survivors	Nonsurvivors
Ronderos Botero <i>et al.</i> <sup>[41]</sup> /retrospective cohort	2	3	3	4	0	0	4	4
Chen <i>et al.</i> <sup>[42]</sup> /retrospective case series	2	3	3	4	0	0	2	2
Giusti <i>et al.</i> <sup>[43]</sup> /prospective cohort	1	2	2	3	1	1	3	3
Liu <i>et al.</i> <sup>[44]</sup> /retrospective cohort	0	4	1	5	2	4	4	4
Liu <i>et al.</i> <sup>[23]</sup> /retrospective cohort	-	-	-	-	0	1	2	3
Luo <i>et al.</i> <sup>[45]</sup> /retrospective cohort	0	3	3	6	0	0	4	4
Martin-Rojas <i>et al.</i> <sup>[24]</sup> /retrospective cohort	-	-	-	-	0	1	2	3
Shang <i>et al.</i> <sup>[46]</sup> /retrospective cohort	0	3	1	4	0	1	4	4
Tang <i>et al.</i> <sup>[4]</sup> /retrospective cohort	0	2	2	4	0	0	6	6
Tang <i>et al.</i> <sup>[10]</sup> /retrospective cohort	2	4	3	5	0	0	4	4
Wang <i>et al.</i> <sup>[47]</sup> /training cohort	0	0	2	2	0	0	6	6
Wang <i>et al.</i> <sup>[47]</sup> /validation cohort	0	2	3	5	0	0	6	6
Wang <i>et al.</i> <sup>[48]</sup> /retrospective cohort	0	3	3	4	0	0	4	4
Wang <i>et al.</i> <sup>[49]</sup> /retrospective case series	3	3	4	4	2	3	4	5
Wu <i>et al.</i> <sup>[50]</sup> /retrospective cohort	0	2	1	3	0	0	4	4
Xu <i>et al.</i> <sup>[51]</sup> /retrospective cohort	0	0	4	4	2	2	4	4
Yang <i>et al.</i> <sup>[52]</sup> /retrospective cohort	0	0	4	4	2	2	4	4
Zhou <i>et al.</i> <sup>[53]</sup> /retrospective cohort	0	3	1	4	1	2	3	4

ISTH=International Society on Thrombosis and Hemostasis; SIC=Sepsis-induced coagulopathy

pro-coagulant pattern.<sup>[10]</sup> consistent with the results of Tang *et al.*, a retrospective cohort study by Luan *et al.* illustrated that patients with ISTH score  $\geq 2$  (COVID-19 associated coagulopathy patients) have higher rates of admission in ICU (42.6% vs. 16.1%), and higher incidence of acute hepatic injury, acute respiratory distress syndrome, and invasive ventilation requirement. These results confirmed that ISTH score  $\geq 2$  is an essential index in COVID-19 patients' triage.<sup>[56]</sup>

Only the nonsurvivor population of one study passed the SIC threshold, and none fulfilled the criteria for DIC when the minimum possible scores were calculated. However, the max-ISTH reached the overt DIC threshold in four and five patient populations in nonsurvivors and severe groups, compared to only one nonsevere patient population. Hence, it appears that using ISTH scores assists physicians to better predict prognosis and adjust management. Considering the extent of missing data for calculating the SIC score, according to the max-SICs, almost all severe and nonsevere patients in these studies were prone to DIC.

ISTH and SIC offer that decreased platelet and fibrinogen, elevated D-dimer/FDP, prolonged PT/increased INR, and a higher level of SOFA score increase the likelihood of DIC.<sup>[57]</sup> Reviewing these parameters in the enrolled studies revealed that although most parameters did not meet the scoring threshold, the changes from the normal range in these parameters in severe cases and nonsurvivors were

consistent with biomarker changes offered by ISTH and SIC, which showed a significant difference when compared to that of nonsevere and survivor patients. One major reason for not meeting the ISTH DIC/SIC threshold can be that all studies only evaluated coagulation parameters at the point of admission and failed to monitor the changes throughout the disease course. The importance of dynamic monitoring of hematological and coagulation parameters in optimizing the management of COVID-19 patients was evident in Liao *et al.* article. In their study, D-dimer, SIC, and overt DIC scores increased over time in the nonsurvivors. The median SIC score reached the diagnostic threshold ( $\geq 4$ ) on day 10, whereas the median ISTH score reached the overt DIC threshold ( $\geq 5$ ) after day 19.<sup>[22]</sup> However, it is worth mentioning that despite the predictive value of ISTH/SIC scores, they are best used when interpreted in the clinical context and during regular monitoring. Accordingly, if the clinical feature is not suggestive of DIC, using these scoring systems is not beneficial even if the defined scores are met.<sup>[58]</sup>

Among all introduced parameters, D-dimer was the most reported data and the most consistent coagulation abnormality that reached the scoring threshold on admission in the included studies, which raised the patients' ISTH score. Pooled data congruently confirmed a significant D-dimer/FDP elevation, PT/INR prolongation, and a higher SOFA score in patients who were severely ill or died from COVID-19. The SOFA score, as a highly sensitive and specific



score for tracking the extent of organ failure to predict mortality, especially in ICU patients, significantly added to the odds of DIC in severe illness. Although most studies highlighted notably lower platelet counts in aggravated illness and deaths, in two studies, the baseline platelet count contradictorily showed a statistically significant rise in severe infection,<sup>[22,29]</sup> which can be explained by the role of platelets as an inflammatory mediator.<sup>[59]</sup> As for fibrinogen, most results were counter-intuitively in line with a remarkable increase in baseline fibrinogen in critically ill patients and nonsurvivors. This discrepancy with what is expected in DIC patients can be justified by the multifaceted role of fibrinogen and the pro-inflammatory and prothrombotic nature of COVID-19 infection.<sup>[60,61]</sup> It seems that the rise in fibrinogen concentration is responsive to the initial cytokine release, followed by a gradual fall in the disease course. The studies that monitored fibrinogen dynamically during the disease corroborated this hypothesis as the higher fibrinogen on admission in severe cases remarkably dropped in the late phase.<sup>[62]</sup>

### Strength and limitations

The present study provides a comprehensive and relatively large-scale review of all available data on the diagnostic and prognostic utility of the ISTH/SIC scoring system in COVID-associated coagulopathy. However, some potential limitations should be taken into account. First, there was some level of heterogeneity. Except for two studies, the rest included studies with retrospective and nonrandomized design, with most of them not considering the control group. Second, most studies lacked the components needed for accurate ISTH and SIC score calculation. Finally, there was a discrepancy between studies in choosing guidelines for classifying COVID-19 illness as severe or nonsevere.

### CONCLUSION

This systematic review implies that according to reported and calculated ISTH and SIC scores, there is a positive correlation between higher scores and disease severity and mortality rate. Despite the high prevalence of coagulation abnormalities and DIC in critically ill COVID-19 patients and its prognostic value, physicians relied mainly on their clinical suspicion and routine lab tests instead of using a specific scoring system like ISTH and SIC for diagnosing DIC. Given that timely management of DIC improves outcomes and reduces costs, detection in the initial stages is essential. Therefore, health-care providers should use highly valued criteria that encompass all relevant markers such as ISTH and SIC while assessing suspicious patients for DIC and requesting lab tests on admission and during the disease course. The full picture of the ISTH and SIC scoring system in the management of COVID-19 coagulopathy is still incomplete, and additional research needs to be done to

establish its effectiveness. We recommend more prospective research with further emphasis on ISTH and SIC criteria and serial monitoring of relevant markers in detecting COVID-associated DIC, which provides an accurate guide for evaluating COVID-19 patients and distinguishing those prone to more severe disease.

### Financial support and sponsorship

Nil.

### Conflicts of interest

There are no conflicts of interest.

### REFERENCES

- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, *et al.* Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395:497-506.
- Parker BM, Heart VJ, Rattan RJ. Coagulopathy in COVID-19: Review and Recommendations. 2020. Available from: [https://www.facs.org/-/media/files/covid19/umiami\\_study\\_uses\\_of\\_coagulopathy.ashx](https://www.facs.org/-/media/files/covid19/umiami_study_uses_of_coagulopathy.ashx).
- Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, *et al.* Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med* 2020;382:1708-20.
- Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost* 2020;18:844-7.
- American Society of Hematology. COVID-19 and Coagulopathy: Frequently Asked Questions 2020. Available from: <https://www.hematology.org/covid-19/covid-19-and-coagulopathy>. [Last accessed on 2020 Nov 15].
- Deng Y, Liu W, Liu K, Fang YY, Shang J, Zhou L, *et al.* Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: A retrospective study. *Chin Med J (Engl)* 2020;133:1261-7.
- Levi M, van der Poll T. Coagulation and sepsis. *Thromb Res* 2017;149:38-44.
- Schmitt FCF, Manolov V, Morgenstern J, Fleming T, Heitmeier S, Uhle F, *et al.* Acute fibrinolysis shutdown occurs early in septic shock and is associated with increased morbidity and mortality: Results of an observational pilot study. *Ann Intensive Care* 2019;9:19.
- Gupta N, Zhao YY, Evans CE. The stimulation of thrombosis by hypoxia. *Thromb Res* 2019;181:77-83.
- Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *J Thromb Haemost* 2020;18:1094-9.
- Taylor FB Jr., Toh CH, Hoots WK, Wada H, Levi M; Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. *Thromb Haemost* 2001;86:1327-30.
- Tal S, Spectre G, Kornowski R, Perl L. Venous thromboembolism complicated with COVID-19: What do we know so far? *Acta Haematol* 2020;143:417-24.
- Iba T, Nisio MD, Levy JH, Kitamura N, Thachil J. New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: A retrospective analysis of a nationwide survey. *BMJ Open* 2017;7:e017046.

14. Toh CH, Dennis M. Disseminated intravascular coagulation: Old disease, new hope. *BMJ* 2003;327:974-7.
15. Fourrier FJ. Coagulations intra-vasculaires disséminées [En: Disseminated Intravascular Coagulation]. French. *Sang Thrombose Vaisseaux* 2003;15:333-9.
16. Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, Deutschman CS, *et al.* Developing a new definition and assessing new clinical criteria for septic shock: For the third international consensus definitions for sepsis and septic shock (Sepsis-3). *JAMA* 2016;315:775-87.
17. Iba T, Levy JH, Warkentin TE, Thachil J, van der Poll T, Levi M, *et al.* Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. *J Thromb Haemost* 2019;17:1989-94.
18. Peterson J, Welch V, Losos M, Tugwell PJ. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2011. Available from: [http://www.ohri.ca/programs/clinical\\_epidemiology/oxford.asp](http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp) [Last accessed on 2020 Nov 15].
19. He B, Wang J, Wang Y, Zhao J, Huang J, Tian Y, *et al.* The metabolic changes and immune profiles in patients With COVID-19. *Front Immunol* 2020;11:2075.
20. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *Int J Surg* 2010;8:336-41.
21. Bao C, Tao X, Cui W, Yi B, Pan T, Young KH, *et al.* SARS-CoV-2 induced thrombocytopenia as an important biomarker significantly correlated with abnormal coagulation function, increased intravascular blood clot risk and mortality in COVID-19 patients. *Exp Hematol Oncol* 2020;9:16.
22. Liao D, Zhou F, Luo L, Xu M, Wang H, Xia J, *et al.* Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: A retrospective cohort study. *Lancet Haematol* 2020;7:e671-8.
23. Liu Y, Gao W, Guo W, Guo Y, Shi M, Dong G, *et al.* Prominent coagulation disorder is closely related to inflammatory response and could be as a prognostic indicator for ICU patients with COVID-19. *J Thromb Thrombolysis* 2020;50:825-32.
24. Martín-Rojas RM, Pérez-Rus G, Delgado-Pinos VE, Domingo-González A, Regalado-Artamendi I, Alba-Urdiales N, *et al.* COVID-19 coagulopathy: An in-depth analysis of the coagulation system. *Eur J Haematol* 2020;105:741-50.
25. White D, MacDonald S, Edwards T, Bridgeman C, Hayman M, Sharp M, *et al.* Evaluation of COVID-19 coagulopathy; laboratory characterization using thrombin generation and nonconventional haemostasis assays. *Int J Lab Hematol* 2021;43:123-30.
26. Huang H, Cai S, Li Y, Li Y, Fan Y, Li L, *et al.* Prognostic factors for COVID-19 pneumonia progression to severe symptom based on the earlier clinical features: A retrospective analysis. *Front Med (Lausanne)* [internet] 2020;7:557453. Doi: 10.3389/fmed.2020.557453. Available from: <https://pubmed.ncbi.nlm.nih.gov/33123541/>. [Last accessed on 2020 Nov 15].
27. Li T, Lu L, Zhang W, Tao Y, Wang L, Bao J, *et al.* Clinical characteristics of 312 hospitalized older patients with COVID-19 in Wuhan, China. *Arch Gerontol Geriatr* [Internet]. 2020;91:104185. doi: 10.1016/j.archger.2020.104185. Available from: <https://pubmed.ncbi.nlm.nih.gov/32688107/>. [Last accessed on 2020 Nov 15].
28. Li Z, Wu M, Yao J, Guo J, Liao X, Song S, *et al.* Caution on kidney dysfunctions of COVID-19 patients. *medRxiv* [preprint]. 2020. Available from: <https://www.medrxiv.org/content/10.1101/2020.02.08.20021212v2>.
29. Liu D, Cui P, Zeng S, Wang S, Feng X, Xu S, *et al.* Risk factors for developing into critical COVID-19 patients in Wuhan, China: A multicenter, retrospective, cohort study. *EClinicalMedicine* [Internet]. 2020;25:100471. doi: 10.1016/j.eclinm.2020.100471. Available from: <https://pubmed.ncbi.nlm.nih.gov/32840491/>. [Last accessed on 2020 Nov 15].
30. Qian GQ, Yang NB, Ding F, Ma AH, Wang ZY, Shen YF, *et al.* Epidemiologic and clinical characteristics of 91 hospitalized patients with COVID-19 in Zhejiang, China: A retrospective, multi-centre case series. *QJM* 2020;113:474-81.
31. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, *et al.* Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA* 2020;323:1061-9.
32. Yu C, Lei Q, Li W, Wang X, Li W, Liu W. Epidemiological and clinical characteristics of 1663 hospitalized patients infected with COVID-19 in Wuhan, China: A single-center experience. *J Infect Public Health* 2020;13:1202-9.
33. Zhang G, Hu C, Luo L, Fang F, Chen Y, Li J, *et al.* Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China. *J Clinical Virol* [Internet]. 2020;127:104364. doi: 10.1016/j.jcv.2020.104364. Available from: <https://pubmed.ncbi.nlm.nih.gov/32311650/> [Last accessed on 2020 Nov 15].
34. Han H, Yang L, Liu R, Liu F, Wu KL, Li J, *et al.* Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. *Clin Chem Lab Med* 2020;58:1116-20.
35. Yu HH, Qin C, Chen M, Wang W, Tian DS. D-dimer level is associated with the severity of COVID-19. *Thromb Res* 2020;195:219-25.
36. Zhang Y, He L, Chen H, Lu S, Xiong Y, Liu J, *et al.* Manifestations of blood coagulation and its relation to clinical outcomes in severe COVID-19 patients. *Retrospect Anal* 2020;42:766-72.
37. Liu J, Tu C, Zhu M, Wang J, Yang C, Liu W, *et al.* Exploring the Law of Development and Prognostic Factors of Common and Severe COVID-19: A Retrospective Case-Control Study in 122 Patients with Complete Course of Disease. SSRN [preprint]. 2020 SSRN 3555209. Available from: <https://dx.doi.org/10.2139/ssrn.3555209>.
38. Long H, Nie L, Xiang X, Li H, Zhang X, Fu X, *et al.* D-dimer and prothrombin time are the significant indicators of severe COVID-19 and poor prognosis. *Biomed Res Int* [Internet]. 2020;6159720. doi: 10.1155/2020/6159720. Available from: <https://pubmed.ncbi.nlm.nih.gov/32596339/> [Last accessed on 2020 Nov 15].
39. Gao Y, Li T, Han M, Li X, Wu D, Xu Y, *et al.* Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. *J Med Virol* 2020;92:791-6.
40. Zeng DX, Xu JL, Mao QX, Liu R, Zhang WY, Qian HY, *et al.* Association of Padua prediction score with in-hospital prognosis in COVID-19 patients. *QJM* 2020;113:789-93.
41. Ronderos Botero DM, Omar AM, Sun HK, Mantri N, Fortuzi K, Choi Y, *et al.* COVID-19 in the healthy patient population: Demographic and clinical phenotypic characterization and predictors of in-hospital outcomes. *Arterioscler Thromb Vasc Biol* 2020;40:2764-75.
42. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, *et al.* Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. *BMJ* 2020;368:m1091.
43. Giusti B, Gori AM, Alessi M, Rogolino A, Lotti E, Poli D, *et al.* Sars-CoV-2 induced coagulopathy and prognosis in hospitalized patients: A snapshot from Italy. *Thromb Haemost* 2020;120:1233-6.
44. Liu J, Zhang S, Wu Z, Shang Y, Dong X, Li G, *et al.* Clinical outcomes of COVID-19 in Wuhan, China: A large cohort study. *Ann Intensive Care* 2020;10:99.
45. Luo X, Xia H, Yang W, Wang B, Guo T, Xiong J, *et al.* Characteristics of patients with COVID-19 during epidemic ongoing outbreak in Wuhan, China. *medRxiv* [preprint]. 2020. Available from: <https://doi.org/10.1101/2020.03.19.20033175>. [Last accessed on 2020 Nov 15].
46. Shang Y, Liu T, Wei Y, Li J, Shao L, Liu M, *et al.* Scoring systems for predicting mortality for severe patients with COVID-19. *EClinicalMedicine* [Internet]. 2020;24:100426. doi: 10.1016/j.eclinm.2020.100426.

- eclinm.2020.100426. Available from: <https://pubmed.ncbi.nlm.nih.gov/32766541/> [Last accessed 2020 Nov 15].
47. Wang K, Zuo P, Liu Y, Zhang M, Zhao X, Xie S, *et al.* Clinical and laboratory predictors of in-hospital mortality in patients with coronavirus disease-2019: A cohort study in Wuhan, China. *Clin Infect Dis* 2020;71:2079-88.
  48. Wang L, He W, Yu X, Hu D, Bao M, Liu H, *et al.* Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up. *J Infect* 2020;80:639-45.
  49. Wang ZH, Shu C, Ran X, Xie CH, Zhang L. Critically ill patients with coronavirus disease 2019 in a designated ICU: Clinical features and predictors for mortality. *Risk Manag Healthc Policy* 2020;13:833-45.
  50. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, *et al.* Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Intern Med* 2020;180:934-43.
  51. Xu J, Yang X, Yang L, Zou X, Wang Y, Wu Y, *et al.* Clinical course and predictors of 60-day mortality in 239 critically ill patients with COVID-19: A multicenter retrospective study from Wuhan, China. *Crit Care* 2020;24:394.
  52. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, *et al.* Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. *Lancet Respir Med* 2020;8:475-81.
  53. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, *et al.* Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. *Lancet* 2020;395:1054-62.
  54. Bakhtiari K, Meijers JC, de Jonge E, Levi M. Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation. *Crit Care Med* 2004;32:2416-21.
  55. Levi M, Meijers JC. DIC: Which laboratory tests are most useful. *Blood Rev* 2011;25:33-7.
  56. Luan YY, Liu Y, Liu XY, Yu BJ, Chen RL, Peng M, *et al.* Coronavirus disease 2019 (COVID-19) associated coagulopathy and its impact on outcomes in Shenzhen, China: A retrospective cohort study. *Thromb Res* 2020;195:62-8.
  57. Toh C, Hoots W; SSC on Disseminated Intravascular Coagulation of the ISTH. The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: A 5-year overview. *J Thromb Haemost* 2007;5:604-6.
  58. Görlinger K, Dirkmann D, Gandhi A, Simioni P. COVID-19-associated coagulopathy and inflammatory response: What do we know already and what are the knowledge gaps? *Anesth Analg* 2020;131:1324-33.
  59. Herter JM, Rossaint J, Zarbock A. Platelets in inflammation and immunity. *J Thromb Haemost* 2014;12:1764-75.
  60. Luyendyk JP, Schoenecker JG, Flick MJ. The multifaceted role of fibrinogen in tissue injury and inflammation. *Blood* 2019;133:511-20.
  61. Hayıroğlu Mİ, Çınar T, Tekkeşin Aİ. Fibrinogen and D-dimer variances and anticoagulation recommendations in Covid-19: Current literature review. *Rev Assoc Med Bras (1992)* 2020;66:842-8.
  62. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, *et al.* Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ [Internet]* 2020;368:m1091. doi: 10.1136/bmj.m1091. Available from: <https://pubmed.ncbi.nlm.nih.gov/32217556/>. [Last accessed on 2020 Nov 15].